Nanomedicines in Cancer Research: An Overview

Kumari, Baby; Hora, Amandeep; Mallick, Maj Abhishek

doi:10.5958/2319-1198.2017.00002.1

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the year 2004, the Nanotechnology Characterization Laboratory (NCL) was launched by the National Cancer Institute (NCI), USA, to boost the process of translating cancer nanomedicine into clinics. 142 The NCI and NCL are working closely with the U.S. Food and Drug Administration (FDA) and National Institute of Standards and Technology. The NCL, in collaboration with 80 industries, studied nearly 300 nanodrug formulations and put 7 nanomedicines into clinical trials over the span of 9 years.…”

Section: Policies Regulation and Marketmentioning

confidence: 99%

“…The NCL, in collaboration with 80 industries, studied nearly 300 nanodrug formulations and put 7 nanomedicines into clinical trials over the span of 9 years. 142 It also developed 40 standard protocols for the characterization of nanoformulations. FDA, a regulatory agency of the United States, recognized a nanotechnology-based spectrum of products including drugs.…”

Section: Policies Regulation and Marketmentioning

confidence: 99%

Section: Policies Regulation and Marketmentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications

Kumar

Dalvi

Siril

2020

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

In the foreseeable future, the pharmaceuticals market, nanomedicine, and healthcare systems will largely depend on the drug nanoparticle formulation technology. Perceiving this, scientists around the world are reporting each day a significant amount of research work focusing on the fundamentals of nanocrystallization and performance enhancement. The nanocrystallization strategies' industrial applications mainly depend on the ability of the technique to produce nanoparticles of active pharmaceutical ingredients (APIs) with controlled particle size, narrow size distribution, stability, reproducibility, high solid loading, scale-up feasibility, suitabilty for a range of APIs, and cost-effectiveness. There are plenty of reports witnessing performance improvements of nanodrugs. The harmony between the nanocrystallization strategies, performance of nanodrugs, scale-up producibility, and industrial challenges remains an untold and unsummarized story in the field of pharmaceutical nanotechnology. This review is devoted to comprehensively discussing the promising nanocrystallization strategies, fundamental concepts, and promising results of nanodrugs. We have also reviewed the progress toward commercialization and market based on nanodrugs, further challenges toward industrial application, and the future direction of pharmaceutical technologies and their impact on the future of the healthcare system.

show abstract

Section: Policies Regulation and Marketmentioning

confidence: 99%

Section: Policies Regulation and Marketmentioning

confidence: 99%

Section: Policies Regulation and Marketmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications

Kumar

Dalvi

Siril

2020

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…The 10-year survival rate for Stage IA is 93%, while patients diagnosed at Stage IV have a 10-year survival rate of 10-15% only (16)(17)(18). Moreover, the cost of treating melanoma increases dramatically with later stages of the disease (19)(20)(21). In addition to the clinical and histological examination, many new techniques have been utilized to aid early detection of melanoma.…”

Section: Nanomedicine For Melanoma Detection and Treatmentmentioning

confidence: 99%

“…Nanomaterials' size range matches cellular organelles, other molecules involved in intracellular events, as signaling pathways, and/or molecules involved in cell to cell communication (16,20). The nanomaterials bio-distribution is dependent on the surface charge, biodegradability, size, their distinct biological properties, and shape (19,(21)(22)(23)(24)(25). Nanoparticles (NPs) or nanocapsules are the most common shape for nanomaterials used as drug delivery systems.…”

Section: Nanomedicine For Melanoma Detection and Treatmentmentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

Nanomedicines in Cancer Research: An Overview

Cited by 2 publications

References 0 publications

Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications

Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Contact Info

Product

Resources

About